Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s What Happened

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $22.33 and last traded at $22.68, with a volume of 849610 shares. The stock had previously closed at $24.39.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Down 7.0 %

The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -30.65 and a beta of -2.75. The business has a 50-day moving average of $28.14 and a two-hundred day moving average of $34.35.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently modified their holdings of the stock. Woodline Partners LP grew its stake in shares of Structure Therapeutics by 0.7% in the 4th quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after purchasing an additional 2,328 shares during the period. Vestal Point Capital LP grew its stake in shares of Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after purchasing an additional 575,000 shares during the period. Twinbeech Capital LP grew its stake in shares of Structure Therapeutics by 34.3% in the 4th quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock valued at $767,000 after purchasing an additional 7,220 shares during the period. Tema Etfs LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at approximately $1,203,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Structure Therapeutics by 8.4% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,520 shares of the company’s stock valued at $529,000 after purchasing an additional 1,520 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.